What is the appropriate management for a patient with chickenpox, including supportive care, isolation, fever control, antipruritic measures, and indications for antiviral therapy?

Chickenpox Management

For immunocompetent patients with uncomplicated chickenpox, supportive care with strict hygiene measures and antipyretics (avoiding ibuprofen) is sufficient, while high-risk groups—including adults, immunocompromised patients, and pregnant women—require early antiviral therapy with oral acyclovir or valacyclovir within 24 hours of rash onset, and severely ill or immunocompromised patients need intravenous acyclovir 10 mg/kg every 8 hours. 1

Isolation and Infection Control

• Isolate patients in a well-ventilated room until all lesions have completely crusted (typically 5–7 days after rash onset), as chickenpox remains contagious through direct contact with vesicular fluid and aerosolized droplets. 2, 3
• Implement airborne and contact precautions in healthcare settings, with physical separation of at least 6 feet from other patients. 3
• Avoid contact with high-risk individuals—including pregnant women, immunocompromised patients, and neonates—until all lesions have scabbed. 4
• Household contacts who are seronegative and HIV-negative should receive varicella vaccination to prevent transmission to susceptible HIV-infected or immunocompromised household members. 4

Supportive Care and Symptom Management

Hygiene and Skin Care

• Bathe daily with stringent soaks (e.g., colloidal oatmeal baths) to reduce pruritus and prevent secondary bacterial skin infections, particularly Group A streptococcus and necrotizing fasciitis. 2, 5
• Change bed linens and clothing daily to maintain cleanliness and reduce bacterial colonization. 2
• Keep fingernails short and clean to minimize excoriation and secondary infection risk. 5
• Avoid applying topical corticosteroids to active vesicular lesions, as they increase the risk of disseminated infection and severe disease. 3

Fever Control

• Use acetaminophen (paracetamol) for fever control; the standard pediatric dose is 10–15 mg/kg every 4–6 hours. 5, 6
• Avoid ibuprofen and other NSAIDs, as they are associated with increased risk of severe secondary bacterial infections, including necrotizing fasciitis and invasive Group A streptococcal disease. 5
• Apply topical ice or cold packs to reduce pain and swelling during the acute vesicular phase. 3

Antipruritic Measures

• Oral antihistamines (e.g., diphenhydramine or chlorpheniramine) can be used to control itching, particularly at night to improve sleep. 3, 6
• Calamine lotion or cooling gels may provide symptomatic relief but do not alter disease course. 2

Antiviral Therapy Indications

High-Risk Groups Requiring Treatment

Initiate oral antiviral therapy within 24 hours of rash onset (ideally within the first 24 hours when viral shedding peaks) for the following groups: 1, 2

• All adults and adolescents ≥13 years, who have significantly higher complication rates than children. 1, 2
• Immunocompromised patients, including those with HIV infection, active chemotherapy, organ transplantation, or chronic immunosuppressive therapy (e.g., corticosteroids >20 mg/day for >2 weeks, biologics, thiopurines). 1, 2, 4
• Pregnant women, due to increased risk of varicella pneumonia and vertical transmission. 2, 4
• Patients with chronic skin or lung disease (e.g., eczema, asthma requiring oral corticosteroids). 1, 7
• Neonates with perinatal varicella exposure. 2
• Patients with secondary household cases, who typically develop more severe disease. 1

Oral Antiviral Regimens (Immunocompetent Patients)

• Acyclovir 800 mg orally five times daily for 7–10 days is the standard regimen, though the frequent dosing may reduce adherence. 1, 3
• Valacyclovir 1000 mg orally three times daily for 7 days offers superior bioavailability and improved adherence compared to acyclovir. 8, 3
• Continue treatment until all lesions have completely scabbed, not just for an arbitrary 7-day period. 4, 3

Intravenous Acyclovir Indications

Switch to intravenous acyclovir 10 mg/kg every 8 hours for the following scenarios: 1, 9, 4

• Disseminated chickenpox (multi-dermatomal involvement, visceral organ involvement including pneumonia, hepatitis, or encephalitis, or hemorrhagic lesions). 1, 3
• Severe immunosuppression (active chemotherapy, HIV with CD4 <200, organ transplant recipients). 1, 9
• Central nervous system complications (encephalitis, meningitis, cerebellar ataxia). 3, 1
• Inability to tolerate or absorb oral medications. 3
• Pregnant women with varicella pneumonia or other serious complications. 2, 3
• Lack of clinical improvement after 7–10 days of oral therapy, suggesting possible acyclovir resistance. 3

Continue IV acyclovir for a minimum of 7–10 days and until all lesions have completely scabbed, with close monitoring of renal function. 4, 3

Immunocompromised Patients: Special Considerations

• Temporarily reduce or discontinue immunosuppressive medications when clinically feasible in cases of disseminated or invasive chickenpox. 4, 3
• High-dose IV acyclovir (10 mg/kg every 8 hours) remains the treatment of choice for severely compromised hosts, as oral therapy may be inadequate due to impaired absorption and higher viral loads. 9, 3
• For acyclovir-resistant VZV (rare in immunocompetent patients but occurs in up to 7% of immunocompromised patients), use foscarnet 40 mg/kg IV every 8 hours until clinical resolution. 9, 3
• Cidofovir may be used as an alternative for resistant VZV infection. 9

Post-Exposure Prophylaxis

Varicella-Zoster Immune Globulin (VZIG)

Administer VZIG as soon as possible but within 96 hours after exposure to the following high-risk groups: 4, 3

• VZV-susceptible (seronegative or no history of chickenpox) HIV-infected children and adults. 4
• VZV-susceptible pregnant women, to prevent maternal complications and congenital varicella syndrome. 4, 3
• Immunocompromised patients (organ transplant recipients, active chemotherapy, severe immunosuppression). 3
• Premature newborns <28 weeks gestation or <1,000 g. 3
• Neonates whose mothers develop chickenpox 5 days before to 2 days after delivery. 2

Alternative Post-Exposure Prophylaxis

• If VZIG is unavailable or >96 hours have passed since exposure, initiate oral acyclovir 800 mg four times daily beginning 7–10 days after exposure and continuing for 7 days. 4, 9
• Varicella vaccine within 3–5 days of exposure may modify disease in immunocompetent, seronegative individuals. 3

Vaccination Considerations

• Live attenuated varicella vaccine is contraindicated in HIV-infected adults and severely immunocompromised children due to risk of disseminated viral infection. 4, 9
• Asymptomatic, non-immunosuppressed HIV-infected children (CDC immunologic category 1) may receive live attenuated varicella vaccine at 12–15 months of age. 4
• After recovery from acute chickenpox, consider the recombinant zoster vaccine (Shingrix) for adults ≥50 years to prevent future herpes zoster episodes. 3

Monitoring and Follow-Up

Renal Function Monitoring

• Obtain baseline serum creatinine before initiating acyclovir or valacyclovir, as both drugs are renally eliminated and can cause crystalluria and obstructive nephropathy in up to 20% of patients. 3
• For IV acyclovir, monitor renal function at initiation and once or twice weekly during treatment, with dose adjustments for creatinine clearance <50 mL/min. 3
• Ensure adequate hydration throughout antiviral therapy to reduce nephrotoxicity risk. 3

Signs of Deterioration Requiring Urgent Evaluation

• Respiratory symptoms (cough, dyspnea, tachypnea) suggesting varicella pneumonia, which occurs in 10–20% of adults. 5, 1
• Neurological changes (altered mental status, severe headache, ataxia, seizures) indicating CNS involvement. 5, 3
• Hemorrhagic or necrotic lesions, which suggest severe disease or secondary bacterial infection. 5, 1
• Persistent fever >3 days after rash onset or recurrence of fever after initial defervescence, raising concern for secondary bacterial infection. 5
• Elevated transaminases, which may indicate VZV hepatitis requiring escalation to IV therapy. 3

Common Pitfalls to Avoid

• Do not delay antiviral therapy beyond 24 hours of rash onset in high-risk patients, as efficacy diminishes rapidly after the first day. 1, 3
• Do not use ibuprofen for fever control, as it significantly increases the risk of necrotizing fasciitis and invasive streptococcal disease. 5
• Do not apply topical corticosteroids to active vesicular lesions, as they promote viral dissemination. 3
• Do not discontinue antiretroviral therapy in HIV-infected patients during acute chickenpox unless drug toxicity or interactions necessitate it. 9
• Do not use short-course antiviral regimens (1–3 days) designed for genital herpes, as they are inadequate for VZV infection. 3
• Do not rely on clinical diagnosis alone in immunocompromised patients or atypical presentations; obtain laboratory confirmation via PCR or direct fluorescent antibody testing. 3